AKUMS DRUGS AND PHARMA L
AKUMS · General/Diversified · NSE
₹592
Current Market Price
Fair Value (DCF)
₹1,007
Discount to FV
+70.0%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
52%
ROE
7.7%
Debt/Equity
0.05
WACC
11.1%
Market Cap
₹9,065 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.2%
Return on capital employed
EV / EBITDA
12.4×
Enterprise multiple
Debt / EBITDA
0.3×
Leverage vs earnings
Interest Coverage
12.4×
EBIT covers interest
Current Ratio
2.55×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
7.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹592.1
Bear case
Discount +3.2%
Base case
Discount +41.2%
Bull case
Discount +54.3%
Ratio Trends
AKUMS · last 5 annual periods
ROE
7.7%
ROCE
18.2%
Operating Margin
—
Debt / Equity
0.05×
PE
—
EV / EBITDA
—
Historical Financials
AKUMS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 yfinance | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3647 Cr | ₹3475 Cr | ₹4020 Cr | ₹4118 Cr | ₹4359 Cr | +4.6% |
| EBITDA | ₹-82.2 Cr | ₹309 Cr | ₹131 Cr | ₹533 Cr | ₹631 Cr | — |
| EBIT | ₹-177 Cr | ₹196 Cr | ₹5.0 Cr | ₹376 Cr | — | — |
| PAT | ₹-253 Cr | ₹94.9 Cr | ₹-4.0 Cr | ₹338 Cr | ₹255 Cr | — |
| EPS (diluted) | ₹-16.04 | ₹6.03 | ₹-0.28 | ₹22.60 | — | — |
| CFO | ₹31.9 Cr | ₹177 Cr | ₹498 Cr | ₹465 Cr | ₹1181 Cr | +146.8% |
| CapEx | ₹-258 Cr | ₹-329 Cr | ₹-311 Cr | ₹-272 Cr | ₹-231 Cr | — |
| FCF | ₹-226 Cr | ₹-152 Cr | ₹187 Cr | ₹193 Cr | ₹951 Cr | — |
| Total Assets | ₹3069 Cr | ₹3267 Cr | ₹3516 Cr | ₹4113 Cr | ₹5447 Cr | +15.4% |
| Total Debt | ₹395 Cr | ₹619 Cr | ₹565 Cr | ₹88.2 Cr | ₹157 Cr | -20.5% |
| Shareholders' Equity | ₹622 Cr | ₹717 Cr | ₹709 Cr | ₹3047 Cr | ₹3313 Cr | +51.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AKUMS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
SUDEEPPHRM SUDEEP PHARMA LIMITED | -68.7% | 40 | Data Limited | 28.1% | — |
 SUVEN SUVEN | — | — | Pending | — | — |
SPARC SPARC | — | — | Pending | 157.9% | — |
 SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
 FDC FDC | — | — | Pending | 11.3% | 18.6× |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for AKUMS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. AKUMS DRUGS AND PHARMA L (AKUMS.NS) trades at 592.10 vs a model fair value of 1006.72, a gap of 70.0%. Piotroski F-score: 5/9. Moat label...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AKUMS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AKUMS →
Compare
Head-to-head with peers
Compare AKUMS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AKUMSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.